ChemICare therapeutic product (CIC-39) is a small molecule that acts as a negative modulator of SOCE. CIC-39 is a small organic molecules easily to be synthesized with high potency and selectivity towards SOCE key proteins (STIM1 and ORAI1). Moreover, the compound showed absence of cytotoxicity at the effective concentrations, excellent tolerability and bioavailability, good metabolic stability and pharmacokinetic profiles.
Furthermore, CIC-39 displays high efficacy in Tubular Aggregate Myopathies (TAM), Duchenne muscular Dystrophy (DMD), Acute pancreatitis (AP) mouse models and in an in-vitro model of rheumatoid arthritis (RA).